Cost Analysis of Technetium-99m versus Indocyanine Green for Sentinel Lymph Node Biopsy in Breast Cancer.


Por: Boyanova IMB, Aulina LB, Iglésia M, López-Cano D, Serra-Serra C, Ruiz-Edo N, Salcedo-Pujantell M, Ibañéz JFJ and Gordo SL

Publicada: 1 feb 2026 Ahead of Print: 20 dic 2025
Resumen:
BACKGROUND: Sentinel lymph node biopsy (SLNB) using Technetium-99 (Tc-99) is the standard technique for axillary staging in breast cancer. However, it has logistic issues, especially in hospitals without a nuclear medicine department (NMD). As the sensitivity and specificity of indocyanine green (ICG) are comparable to those of Tc-99, the aim of this study was to perform a cost-benefit analysis of the 2 methods. MATERIALS AND METHODS: A prospective observational cohort of patients undergoing breast cancer surgery was included. Tc-99 and ICG were administered during the same procedure for SLNB. Three clinical pathways were constructed: Tc-99 administration at hospitals without NMD (first clinical pathway), Tc-99 administration at hospitals with NMD (second), and the ICG method (third). A cost comparison between the pathways was performed using the monetary unit of Euros (€). RESULTS: Between April 2021 and April 2024, 112 patients with breast cancer underwent SLNB using Tc-99 and ICG detection. The total cost per patient for the first clinical pathway was €322.29, for the second, €308.29 and for the third, €61.35 per patient. The cumulative cost for 112 patients in the first and second clinical pathways (€37,216.48 and €34,528.48, respectively) resulted to be 5.2 times the cost of the ICG pathway (€6871.2). The use of ICG results in an average saving of approximately 80% of the Tc-99 expenses. CONCLUSION: ICG is a cost-effective option as a tracer for sentinel lymph node biopsy in breast cancer. ICG also offers logistic advantages and it should be considered in clinical practice and protocols.

Filiaciones:
Boyanova IMB:
 General of Surgery Department, Fundación Hospitalarias Barcelona, Barcelona, Spain

Aulina LB:
 Department of Surgery, Universitat Autònoma de Barcelona, Barcelona, Spain

 General of Surgery and Breast Surgery Department, Hospital Universitario Germans Trias i Pujol, Badalona, Spain

Iglésia M:
 Surgical Nurse, General of Surgery Department, General Hospital, Madrid, Spain

López-Cano D:
 General of Surgery and Breast Surgery Department, Consorcio Sanitario del Maresme, Hospital de Mataró, Mataró, Spain

Serra-Serra C:
 Obstetrics and Gynecology Department, Consorcio Sanitario del Maresme, Hospital de Mataró, Mataró, Spain

Ruiz-Edo N:
 General of Surgery and Breast Surgery Department, Consorcio Sanitario del Maresme, Hospital de Mataró, Mataró, Spain

Salcedo-Pujantell M:
 Nuclear Medicine Department, Hospital Universitario Germans Trias i Pujol, Badalona, Spain

:
 Department of Surgery, Universitat Autònoma de Barcelona, Barcelona, Spain

 General of Surgery and Breast Surgery Department, Hospital Universitario Germans Trias i Pujol, Badalona, Spain

Gordo SL:
 General of Surgery and Breast Surgery Department, Consorcio Sanitario del Maresme, Hospital de Mataró, Mataró, Spain

 Human Anatomy and Embryology Unit, Department of Morphological Sciences, Universitat Autònoma de Barcelona, Barcelona, Spain
ISSN: 15268209





Clinical Breast Cancer
Editorial
Elsevier Inc., United States, Estados Unidos America
Tipo de documento: Article
Volumen: 26 Número: 2
Páginas: 50-58
WOS Id: 001676154500001
ID de PubMed: 41570376

MÉTRICAS